Opinion|Videos|July 9, 2024
Predictors of Immunotherapy Response in Limited and Extensive SCLC
Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.
Advertisement
Episodes in this series
- How do we advance the field on which patients with SCLC derive the greatest benefit from IO in both limited stage and extensive stage disease?
- Do we yet know which clinical or molecular characteristics might predict extended survival in ES-SCLC, such as platinum sensitivity or PD-L1 expression?
- For those who experience extended survival, do you continue immunotherapy and how long is that interval?
Advertisement
Related to this article
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
5